相关临床试验
11
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
7
63.6%
尚未招募
2
18.2%
Unknown
2
18.2%
暂无批准数据
- Johns Hopkins Medicine researchers identified N4-acetylcytidine (ac4C), a naturally occurring RNA modification, as a potential way to make mRNA therapies produce more protein inside cells. - Ribosomes traveled nearly twice as fast on ac4C-modified mRNA compared with the industry-standard N1-methylpseudouridine (m1Ψ) platform, preventing ribosomal "traffic jams." - The ac4C platform produced more and better proteins, suggesting future mRNA drugs could achieve therapeutic effects with smaller doses. - The findings, published in Nature and co-led by the NIH, could influence vaccines and treatments for cancer, infectious diseases, and autoimmune conditions.
- The Advisory Council on Parkinson's Research, Care, and Services (ACPRCS) will convene its third meeting in November 2026 as a hybrid event, in person at the Hubert H. Humphrey Building and virtually via HHS Live Streaming. - The meeting will spotlight public-private partnerships for Parkinson's disease and related disorders (PDRD) and feature updates from the Research and Regulatory Program Subcommittee and the Care, Services, and Supports Subcommittee. - All materials and discussion will support the Council's recommendations to the HHS Secretary and the National Plan to End Parkinson's. - Written public comments must be received by October 26 at 5:00 p.m. ET to be shared with the Council at the meeting.
